Trends in Prevalence of Chronic Kidney Disease in the United States.

Background Trends in the prevalence of chronic kidney disease (CKD) are important for health care policy and planning. Objective To update trends in CKD prevalence. Design Repeated cross-sectional study. Setting NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012. Participants Adults aged 20 years or older. Measurements Chronic kidney disease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL/min/1.73 m2, estimated with the Chronic Kidney Disease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g. Results The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence in 2003 to 2004 and in 2011 to 2012). There was little difference in adjusted prevalence of stage 3 and 4 CKD overall in 2003 to 2004 versus 2011 to 2012 after age, sex, race/ethnicity, and diabetes mellitus status were controlled for (P = 0.26). Lack of increase in CKD prevalence since the early 2000s was observed in most subgroups and with an expanded definition of CKD that included persons with higher eGFRs and albuminuria. Limitation Serum creatinine and albuminuria were measured only once in each person. Conclusion In a reversal of prior trends, there has been no appreciable increase in the prevalence of stage 3 and 4 CKD in the U.S. population overall during the most recent decade. Primary Funding Source American Society of Nephrology Foundation for Kidney Research Student Scholar Grant Program, Centers for Disease Control and Prevention, and National Institutes of Health.

[1]  P. Groop,et al.  Incidence of end-stage renal disease in patients with type 1 diabetes. , 2005, Journal of the American Medical Association (JAMA).

[2]  H. Brenner,et al.  CKD Prevalence Varies across the European General Population. , 2016, Journal of the American Society of Nephrology : JASN.

[3]  R. Foley,et al.  ESRD due to Multiple Myeloma in the United States, 2001-2010. , 2016, Journal of the American Society of Nephrology : JASN.

[4]  Yuling Hong,et al.  Trends in Blood Pressure Among Adults With Hypertension: United States, 2003 to 2012 , 2015, Hypertension.

[5]  G. Moon,et al.  Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010 , 2014, BMJ Open.

[6]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[7]  J. Coresh,et al.  Trends in Prevalence and Control of Diabetes in the United States, 19881994 and 19992010 , 2014, Annals of Internal Medicine.

[8]  Barry I. Freedman,et al.  APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.

[9]  Lester R Curtin,et al.  National health and nutrition examination survey: analytic guidelines, 1999-2010. , 2013, Vital and health statistics. Series 2, Data evaluation and methods research.

[10]  Chi-yuan Hsu,et al.  Temporal trends in prevalence of CKD: the glass is half full and not half empty. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Elizabeth Selvin,et al.  Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine- and cystatin C-based estimates. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  V. Jha,et al.  Chronic kidney disease: global dimension and perspectives , 2013, The Lancet.

[13]  Desmond E. Williams,et al.  Albuminuria prevalence in first morning void compared with previous random urine from adults in the National Health and Nutrition Examination Survey, 2009-2010. , 2013, Clinical chemistry.

[14]  Vicki L. Burt,et al.  Trends in Antihypertensive Medication Use and Blood Pressure Control Among United States Adults With Hypertension: The National Health and Nutrition Examination Survey, 2001 to 2010 , 2012, Circulation.

[15]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[16]  Mark E Molitch,et al.  Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. , 2011, The New England journal of medicine.

[17]  Patrick J Heagerty,et al.  Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.

[18]  E. Ford,et al.  Prevalence of Diabetes and High Risk for Diabetes Using A1C Criteria in the U.S. Population in 1988–2006 , 2010, Diabetes Care.

[19]  N. Powe,et al.  Blood Pressure Control Among Persons Without and With Chronic Kidney Disease: US Trends and Risk Factors 1999–2006 , 2009, Hypertension.

[20]  J. Shaw,et al.  International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.

[21]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[22]  R. Foley,et al.  Cystatin C levels in U.S. adults, 1988-1994 versus 1999-2002: NHANES. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[23]  Tom Greene,et al.  Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the Modification of Diet in Renal Disease study equation for estimating glomerular filtration rate (Annals of Internal Medicine (2006) 145, (247-254)) , 2008 .

[24]  A. Go,et al.  The risk of acute renal failure in patients with chronic kidney disease. , 2008, Kidney international.

[25]  J. Coresh,et al.  Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J. Coresh,et al.  Prevalence of chronic kidney disease in the United States. , 2007, JAMA.

[27]  A. Levey,et al.  Chronic kidney disease: common, harmful and treatable--World Kidney Day 2007. , 2007, American journal of nephrology.

[28]  Tom Greene,et al.  Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.

[29]  Richard Goldstein,et al.  Regression Methods in Biostatistics: Linear, Logistic, Survival and Repeated Measures Models , 2006, Technometrics.

[30]  QiupingGu,et al.  Antihypertensive Medication Use Among US Adults With Hypertension , 2006 .

[31]  C. Dillon,et al.  Antihypertensive Medication Use Among US Adults With Hypertension , 2006, Circulation.

[32]  G. Eknoyan,et al.  Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2005, Kidney international.

[33]  A. Bello,et al.  Chronic kidney disease: the global challenge , 2005, The Lancet.

[34]  Charles E. McCulloch,et al.  Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models , 2005 .

[35]  T. Hostetter,et al.  Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. , 2004, Journal of the American Society of Nephrology : JASN.

[36]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[37]  Feng Lin,et al.  The Incidence of End-Stage Renal Disease Is Increasing Faster than the Prevalence of Chronic Renal Insufficiency , 2004, Annals of Internal Medicine.

[38]  E. Vittinghoff,et al.  Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. , 2003, Journal of the American Society of Nephrology : JASN.

[39]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[40]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[41]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[42]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[43]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[44]  H. Parving,et al.  EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY , 1983, The Lancet.

[45]  R. Garrick,et al.  Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD , 2008 .